Last edition
News about "clinical development "
Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development
Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.
Clinical Development | 01/12/2025 | By Dineshwori
Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development
Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.
Clinical Development | 01/12/2025 | By Dineshwori
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Clinical Development | 12/11/2025 | By Dineshwori | 268
GENFIT and EVerZom Partner to Advance Exosome-based Regenerative Technology in ACLF
Under the collaboration, GENFIT and EVerZom will combine expertise to advance EViv, an exosome-based regenerative therapy for ACLF, with GENFIT leading preclinical evaluation and EVerZom providing its bioproduction platform. GENFIT also holds an exclusive option to licence the programme following successful proof-of-concept results.
Clinical Development | 12/11/2025 | By Dineshwori
Health Canada Grants Authorisation for Leqembi (Lecanemab)
BioArctic has the right to commercialise Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialisation in the region.
Clinical Development | 28/10/2025 | By Dineshwori | 130
Through a novel public-private partnership, IAVI, Minapharm and ProBioGen will work together to bolster the innovation ecosystem on the continent and enable sustainable access to urgently-needed products.
Clinical Development | 13/10/2025 | By Dineshwori | 116
US FDA Grants Fast Track Designation to AAV Gene Therapy by Sanofi
The US FDA has granted fast track designation to Sanofi’s SAR446268, an AAV gene therapy for juvenile and adult-onset myotonic dystrophy type 1 (DM1).
Clinical Development | 23/09/2025 | By Dineshwori | 185
Alumis and Kaken Pharmaceutical to Develop ESK-001 in Dermatology in Japan
Under the terms of the agreement, Alumis will receive USD 40 million in upfront and near-term co-development payments from 2025 to 2026, with the potential to earn up to approximately USD 140 million in additional payments based on the achievement of milestones, and field option payments.
Clinical Development | 28/03/2025 | By Aishwarya | 365
Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront
Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.
Clinical Development | 12/02/2025 | By Aishwarya | 339
Verismo Therapeutics Completes Merger to Accelerate Clinical Development
The merger will accelerate the clinical development of SynKIR™-110 and SynKIR™-310 for solid tumor and blood cancer patients, respectively, solidifying Verismo's and HLB Group's collective mission to advance its innovative KIR-CAR platform for patients worldwide.
Clinical Development | 21/12/2024 | By Aishwarya | 539
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy